- BIST10011,722-2.89%
- USD49.45+0.05%
- EUR55.62+0.37%
- GOLD4,195.20+0.34%
- INTEREST37.00%-1.00
- BITCOIN82,300+0.35%
- October 19, 202610°
- BIST10011,722-2.89%
- USD49.45+0.05%
- EUR55.62+0.37%
- GOLD4,195.20+0.34%
- INTEREST37.00%-1.00
- BITCOIN82,300+0.35%
- October 19, 202610°
Eli Lilly is transferring its cash power to acquisitions
Eli Lilly accelerated its acquisition strategy with the revenue power from weight loss drugs. The company committed up to $25 billion for eight deals this year...
Eli Lilly is channeling the strong revenue stream from obesity treatments into the company's growth plan. The pharmaceutical manufacturer has significantly increased its appetite for acquisitions for new drug candidates and different treatment areas.
The official in charge of the company's business development said that Lilly's financial strength has recently reached an extraordinary level, especially thanks to weight loss drugs. He explained that this resource is intended to be transformed into investments that will not only support the company's growth but also enable it to reach more patients in many disease areas.
Highlights
- Lilly has announced upfront spending of more than $10 billion for eight acquisitions so far this year.
- With contingent payments, the total amount can reach up to $25 billion.
- The company's market value has reached approximately $1 trillion.
- Lilly is now targeting not only early-stage and low-cost projects but also more mature and expensive candidates.
- New acquisitions include oncology, neuroscience, cardiometabolic health, immune system, and vaccine areas.
Acquisition strategy is changing
Last year, Lilly spent around $4 billion on approximately 40 deals. This year, the spending pace has clearly accelerated. Management is reshaping the deal-making approach along with the company's size and valuation increase.
The company's market value was around $190 billion in 2021 and has now reached approximately $1 trillion. Thus, Lilly became the first healthcare company to enter the trillion-dollar club, which is dominated by technology companies.
GLP-1 revenues fuel the new era
Previously, Lilly mainly invested in early-stage, cheaper but riskier assets. Now, with the revenue generated by GLP-1 drugs like Mounjaro and Zepbound, it is turning to experimental drugs that are more expensive but have a higher likelihood of success.
The company official said that when a candidate has a strong scientific basis and meaningful potential impact for patients, they are open to paying a higher price. According to him, the issue is not about setting an arbitrary upper limit; it is about the credibility of science and the impact that can be created for patients.
Centessa deal attracted attention
The Centessa Pharmaceuticals acquisition announced by Lilly in March could reach up to $7.8 billion with milestone payments. If completed, this deal will be the second-largest in the company's history. Lilly had acquired Loxo Oncology for $8 billion in 2019.
While some of the company's deals this year focus on main areas such as oncology, neuroscience, cardiometabolic health, and immunology, the three recently announced vaccine company acquisitions are taking Lilly into new fields. Management clearly states that the company may also move beyond its past four main categories.
The door to bigger deals is opening
While the company previously preferred low-risk and early-stage bets, it is now exploring a broader opportunity space. This approach shows that Lilly is not only strengthening its core portfolio but also aiming to grow in new therapeutic areas in the coming years.
Management emphasizes that it is ready to make deals in any area it deems appropriate. This means the company may announce new acquisitions not only in existing categories but also in areas outside its historical trajectory in the upcoming period.
Context: Lilly's move shows that the extraordinary financial power created by obesity drugs is opening a new era not only in sales performance but also in the company's acquisition strategy.
Stay Updated with Ally Daily
Subscribe to be informed about special news, developments and announcements. We will keep you informed.
By signing up, you agree to our Privacy Policy
